These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 24493474

  • 1. Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis.
    Pender MP, Csurhes PA, Smith C, Beagley L, Hooper KD, Raj M, Coulthard A, Burrows SR, Khanna R.
    Mult Scler; 2014 Oct; 20(11):1541-4. PubMed ID: 24493474
    [Abstract] [Full Text] [Related]

  • 2. Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis.
    Fissolo N.
    Mult Scler; 2014 Oct; 20(11):1545. PubMed ID: 24622348
    [No Abstract] [Full Text] [Related]

  • 3. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y, Aïssi-Rothe L, Virion JM, De Carvalho Bittencourt M, Ulas N, Audonnet S, Salmon A, Clement L, Venard V, Jeulin H, Stoltz JF, Decot V, Bensoussan D.
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [Abstract] [Full Text] [Related]

  • 4. Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis.
    Pender MP, Csurhes PA, Smith C, Douglas NL, Neller MA, Matthews KK, Beagley L, Rehan S, Crooks P, Hopkins TJ, Blum S, Green KA, Ioannides ZA, Swayne A, Aftab BT, Hooper KD, Burrows SR, Thompson KM, Coulthard A, Khanna R.
    JCI Insight; 2018 Nov 15; 3(22):. PubMed ID: 30429369
    [Abstract] [Full Text] [Related]

  • 5. Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism.
    Serafini B, Rosicarelli B, Veroni C, Mazzola GA, Aloisi F.
    J Virol; 2019 Dec 15; 93(24):. PubMed ID: 31578295
    [Abstract] [Full Text] [Related]

  • 6. Decreased CD8+ T cell response to Epstein-Barr virus infected B cells in multiple sclerosis is not due to decreased HLA class I expression on B cells or monocytes.
    Pender MP, Csurhes PA, Pfluger CM, Burrows SR.
    BMC Neurol; 2011 Aug 03; 11():95. PubMed ID: 21810280
    [Abstract] [Full Text] [Related]

  • 7. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis.
    Jilek S, Schluep M, Meylan P, Vingerhoets F, Guignard L, Monney A, Kleeberg J, Le Goff G, Pantaleo G, Du Pasquier RA.
    Brain; 2008 Jul 03; 131(Pt 7):1712-21. PubMed ID: 18550621
    [Abstract] [Full Text] [Related]

  • 8. The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis.
    Veroni C, Aloisi F.
    Front Immunol; 2021 Jul 03; 12():665718. PubMed ID: 34305896
    [Abstract] [Full Text] [Related]

  • 9. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
    Nowakowska J, Stuehler C, Egli A, Battegay M, Rauser G, Bantug GR, Brander C, Hess C, Khanna N.
    Cytotherapy; 2015 Sep 03; 17(9):1280-91. PubMed ID: 26276009
    [Abstract] [Full Text] [Related]

  • 10. Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis.
    Pender MP, Csurhes PA, Lenarczyk A, Pfluger CM, Burrows SR.
    J Neurol Neurosurg Psychiatry; 2009 May 03; 80(5):498-505. PubMed ID: 19015225
    [Abstract] [Full Text] [Related]

  • 11. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis.
    Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, Ruggieri S, Gasperini C, Buttari F, Centonze D, Mechelli R, Salvetti M, Borsellino G, Aloisi F, Battistini L.
    PLoS Pathog; 2013 May 03; 9(4):e1003220. PubMed ID: 23592979
    [Abstract] [Full Text] [Related]

  • 12. Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins.
    van Nierop GP, Mautner J, Mitterreiter JG, Hintzen RQ, Verjans GM.
    Mult Scler; 2016 Mar 03; 22(3):279-91. PubMed ID: 26041797
    [Abstract] [Full Text] [Related]

  • 13. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.
    Merlo A, Turrini R, Bobisse S, Zamarchi R, Alaggio R, Dolcetti R, Mautner J, Zanovello P, Amadori A, Rosato A.
    J Immunol; 2010 May 15; 184(10):5895-902. PubMed ID: 20385879
    [Abstract] [Full Text] [Related]

  • 14. Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy.
    Pender MP, Burrows SR.
    Clin Transl Immunology; 2014 Oct 15; 3(10):e27. PubMed ID: 25505955
    [Abstract] [Full Text] [Related]

  • 15. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM, Crawford DH.
    Blood Rev; 2004 Sep 15; 18(3):193-209. PubMed ID: 15183903
    [Abstract] [Full Text] [Related]

  • 16. Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection.
    Pender MP.
    Autoimmun Rev; 2009 Jun 15; 8(7):563-8. PubMed ID: 19254880
    [Abstract] [Full Text] [Related]

  • 17. Antibody producing B lineage cells invade the central nervous system predominantly at the time of and triggered by acute Epstein-Barr virus infection: A hypothesis on the origin of intrathecal immunoglobulin synthesis in multiple sclerosis.
    Otto C, Hofmann J, Ruprecht K.
    Med Hypotheses; 2016 Jun 15; 91():109-113. PubMed ID: 27142157
    [Abstract] [Full Text] [Related]

  • 18. Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis.
    Höllsberg P, Hansen HJ, Haahr S.
    Clin Exp Immunol; 2003 Apr 15; 132(1):137-43. PubMed ID: 12653848
    [Abstract] [Full Text] [Related]

  • 19. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
    Pfeffermann LM, Pfirrmann V, Huenecke S, Bremm M, Bonig H, Kvasnicka HM, Klingebiel T, Bader P, Rettinger E.
    Cytotherapy; 2018 Jun 15; 20(6):839-850. PubMed ID: 29754771
    [Abstract] [Full Text] [Related]

  • 20. Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors.
    Eom HS, Choi BK, Lee Y, Lee H, Yun T, Kim YH, Lee JJ, Kwon BS.
    J Immunother; 2016 Apr 15; 39(3):140-8. PubMed ID: 26938947
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.